WW Earnings

WW reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 172.00M against an estimate of 161.00M, resulting in a 6.64% surprise. The EPS was -0.44, surpassing the expected -0.14 by -214.29% . The stock experienced a 3.52% price change on the earnings day and a -14.43% change over the next five days, reflecting market reactions to the results.

Following WW's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 3.52% on the day of the release. Over the subsequent five days, it saw a -14.43% change. Historically, WW's stock price tends to shift by an average of -1.40% in the 10 days leading up to earnings and -17.95% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate WW’s annual revenue to reach 150.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.4% and EPS estimates Revise Upward by 0.47% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between WW's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.4%, while EPS estimates moved Revise Upward by 0.47% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, WW's stock price typically moves by -1.40% in the 10 days before its earnings and -17.95% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 150.00M.

The earnings call presents mixed signals. While clinical subscriber growth and strategic partnerships, including one with Amazon, are positive, the decline in revenue and behavioral subscribers is concerning. The company's financial health appears stable, with a significant reduction in term loan and cash reserves increase. However, uncertainties in the clinical business and lack of specific guidance on influencer campaign returns temper optimism. The market may react cautiously, resulting in a neutral stock price movement over the next two weeks.